# Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers

> **NCT00666991** · PHASE1 · COMPLETED · sponsor: **CritiTech, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Peritoneal Neoplasms

## Interventions

- **DRUG:** nanoparticulate paclitaxel

## Key facts

- **NCT ID:** NCT00666991
- **Lead sponsor:** CritiTech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666991, "Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00666991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*